^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAL008

    i
    Other names: SAL008, JK08
    Associations

    News

    Trials
    Company:
    Shenzhen Salubris
    Drug class:
    CTLA4 inhibitor, IL-15 stimulant
    Related drugs:
    Associations

    News

    Trials
    14d
    Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=263, Recruiting, Salubris Biotherapeutics Inc | N=149 --> 263
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • SAL008
    7ms
    A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors (SITC 2023)
    Response will be assessed every 9 weeks per RECIST v1. 1.
    Clinical • P1/2 data • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
    |
    CTLA4 expression
    |
    SAL008
    9ms
    Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer (ESMO 2023)
    Conclusions At the dose levels evaluated to date, JK08 has been well tolerated, demonstrating preliminary disease stability & anticipated modulation of target immune cell populations in aggressive heavily pre-treated solid tumors. These results provide an initial characterization of JK08 biology & activity.
    P1/2 data • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
    |
    CD8 expression
    |
    SAL008
    1year
    A phase 1 / 2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors (AACR 2023)
    Four tumor specific expansion cohorts will be initiated once dose and schedule are established from dose escalation and include melanoma, breast cancer, colorectal cancer, and a basket of advanced solid tumors. Response will be assessed every 9 weeks per RECIST v1.1.
    Clinical • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • IL15 (Interleukin 15)
    |
    CTLA4 expression
    |
    SAL008
    over1year
    A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=149, Recruiting, Salubris Biotherapeutics Inc
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    SAL008